CoChat

Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies

Chen, Jonathan H., Pezhouh, Maryam K., Lauwers, Gregory Y., Masia, Ricard · 2017 · American Journal of Surgical Pathology

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

Programmed cell death protein 1 (PD-1) blocking agents are novel immunotherapeutics used for treatment of advanced-stage malignancies. They have shown promise in the treatment of several malignancies, with greater efficacy and better tolerability than cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking agents. However, as with anti-CTLA-4 agents, clinically significant colitis remains an important complication. Although there is growing awareness of the histopathologic features of anti-CTLA-4 therapy, there is little information on the pathologic features of anti-PD-1 colitis. We describe here the histopathologic findings in 8 patients who developed colitis while on anti-PD-1 monotherapy. The most common pattern of injury observed (5/8 cases) was an active colitis with neutrophilic crypt microabscesses and with prominent crypt epithelial cell apoptosis and crypt atrophy/dropout. These latter features are reminiscent of other colitides with prominent apoptosis such as acute graft-versus-host disease or certain drug-induced colitides. The remainder of cases (3/8) showed a lymphocytic colitis-like pattern, characterized by increased intraepithelial lymphocytes and surface epithelial injury. Apoptosis was also often increased in these cases but crypt atrophy/dropout was not present. In patients who experienced recurrence of anti-PD-1 colitis, histologic features were similar to the initial insult but, in addition, features of chronicity developed that mimicked inflammatory bowel disease (basal lymphoplasmacytosis and crypt architectural irregularity, and Paneth cell metaplasia in 1 case). Awareness of the clinical scenario, however, should allow pathologists to suggest anti-PD-1 colitis. Interestingly, recurrent colitis was observed in patients who had been off anti-PD-1 therapy for many months. As anti-PD-1 agents are increasingly used in oncology, we present this series to increase awareness of anti-PD-1 colitis among pathologists, to facilitate its timely diagnosis and treatment.

Overview

Integrity signals

Registry

Crossref · 10.1097/pas.0000000000000829

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 187

Metadata

Authors
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R.
Affiliations
  • Massachusetts General Hospital (US)
  • Johns Hopkins University (US)
  • Moffitt Cancer Center (US)
Corresponding author
  • Chen, Jonathan H.
  • Masia, Ricard
Venue
American Journal of Surgical Pathology
Published
2017-05
Volume
41
Issue
5
Pages
643-654
ISSN
0147-5185 (ISSN-L)
OpenAlex
W2595325983
Cited by
186
References
50
Citations by year
2026: 6 · 2025: 10 · 2024: 22 · 2023: 16 · 2022: 21 · 2021: 30 · 2020: 24 · 2019: 25 · 2018: 22 · 2017: 8
FWCI
9.58
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Surgical Pathology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
immune checkpoint inhibitors, anti-PD-1 therapy, colitis histopathology, lymphocytic colitis, intraepithelial lymphocytes, Paneth cell metaplasia, inflammatory bowel disease mimic, drug-induced colitis, graft-versus-host disease, immune-related adverse events
MeSH terms
Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Antibodies, Antineoplastic Agents, Atrophy, Biopsy, Colectomy, Colitis, Colon, Colonoscopy, Diagnosis, Differential, Enterocolitis, Pseudomembranous, Female, Humans, Immunotherapy, Male, Middle Aged, Predictive Value of Tests, Remission Induction, Retrospective Studies, Severity of Illness Index, Inflammatory Bowel Diseases, Apoptosis, Colitis, Lymphocytic, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. https://app.cochat.ai/papers/10.1097/pas.0000000000000829
The paper
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017). Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000000829

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.